1.
Rev Neurol (Paris)
; 178(3): 278-280, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34274131
2.
Rev Neurol (Paris)
; 177(10): 1262-1265, 2021 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34654546
RESUMO
Patients with chronic neurological diseases may have predisposing risk factors for severe COVID-19 and should be considered as priority candidates for SARS-CoV-2 vaccination. Nevertheless, the safety of RNA vaccine was evaluated in healthy volunteers or in patients with stable chronic medical conditions excluding patients with chronic neurological diseases. We report here the early tolerability of Comirnaty vaccine in 36 patients with chronic neurological diseases and demonstrate good early tolerability, better than found in healthy people in phase 3 trials.
Assuntos
Vacinas contra COVID-19 , COVID-19 , Humanos , SARS-CoV-2 , Vacinas Sintéticas , Vacinas de mRNA
3.
Rev Neurol (Paris)
; 177(10): 1301-1303, 2021 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34229870